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A Serial IVUS Analysis From the HORIZONS-AMI Trial
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Markus Jaster, MD,† So-Yeon Choi, MD, PHD,* Xiaofan Wu, MD, PHD,* Yong He, MD,*
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New York, New York; Berlin, Germany; and Rancho Cordova, California
O B J E C T I V E S The authors sought to report the temporal stability of an untreated, nonculprit lesion
phenotype in patients presenting with ST-segment elevation myocardial infarction (STEMI).
B A C KG ROUND The temporal stability of the untreated, nonculprit lesion phenotype has been
studied using intravascular ultrasound-virtual histology (IVUS) in patients with stable ischemic heart
disease, but not in STEMI patients.
METHOD S As part of a formal substudy of the HORIZONS-AMI (Harmonizing Outcomes With
Revascularization and Stents in Acute Myocardial Infarction) trial, baseline and 13-month follow-up IVUS
was performed in 99 untreated nonculprit lesions in 63 STEMI patients. Lesions were classiﬁed as
pathological intimal thickening (PIT), IVUS–derived thin-cap ﬁbroatheroma (TCFA), thick-cap ﬁbroathe-
roma (ThCFA), ﬁbrotic plaque, or ﬁbrocalciﬁc plaque.
R E S U L T S The frequency of TCFA increased from 41% at baseline to 54% at follow-up, whereas ThCFAs
decreased from 41% to 34% and PIT decreased from 16% to 8%. Among the 41 lesions classiﬁed at baseline
as TCFA, at follow-up, 32 (78%) were still classiﬁed as TCFA, whereas 9 (22%) were classiﬁed as ThCFAs or
ﬁbrotic plaques. An additional 21 lesions at follow-up were newly classiﬁed as TCFA, developing from either
PIT or ThCFA. TCFA at baseline that evolved into non-TCFAs trended toward a more distal location than TCFA
that did not change (p 0.12). In lesions classiﬁed as TCFA, the minimum lumen area (MLA) decreased from
8.1 (interquartile range [IQR]: 7.4 to 8.8) mm2 at baseline to 7.8 (IQR: 7.2 to 8.4) mm2 at follow-up, p  0.05;
this was associated with an increase in percent necrotic core at the MLA site (14% [IQR: 12 to 16] to 19% [IQR:
17 to 22], p  0.0001) and over the entire length of the lesion (14% [IQR: 12 to 16] to 18% [IQR: 17 to 20],
p  0.0001).
CONC L U S I O N S Untreated nonculprit lesions in STEMI patients frequently have TCFA morphology
that does not change during 13-month follow-up and is accompanied by a decrease in MLA and an
increase in necrotic core. (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial
Infarction [HORIZONS-AMI]; NCT00433966) (J Am Coll Cardiol Img 2013;6:86–95) © 2013 by the
American College of Cardiology Foundation
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87utopsy data suggest that rupture of an ather-
omatous plaque with superimposed throm-
bosis is the cause of most acute coronary
syndromes (ACS) and sudden cardiac
death (1–3). A thin-cap fibroatheroma (TCFA)
with a large lipid-rich necrotic core (NC) is partic-
ularly prone to rupture and result in coronary artery
thrombotic occlusion (4–7). Furthermore, 3-vessel
imaging studies in patients with ACS have shown
that the incidence of secondary plaque rupture in
nonculprit lesions is fairly common (8). Intravascu-
lar ultrasound-virtual histology (IVUS) provides
quantitative and qualitative information about
plaque composition and lesion phenotype, includ-
ing plaques prone to cause events (9–12), and may
therefore be useful to assess serial plaque composi-
tion evolution. A previous IVUS study in patients,
mostly with stable ischemic heart disease, demon-
strated that the IVUS lesion phenotype can evolve
and, specifically, that virtual histology– derived
thin-cap fibroatheromas (TCFA) can develop
and/or heal within 1 year (13). No such studies have
been performed in patients with ACS. In the
present study, therefore, we used serial (baseline
and follow-up) IVUS to assess the dynamic nature
of nonculprit coronary artery lesion morphology in
patients with ST-segment elevation myocardial in-
farction (STEMI), in particular to evaluate the
development and evolution of TCFA.
M E T H O D S
Study population. HORIZONS-AMI (Harmo-
izing Outcomes With Revascularization and
tents in Acute Myocardial Infarction) was a
rospective, open-label, multicenter, dual-arm,
 2 factorial randomized trial in patients with
TEMI. The 2 randomization arms consisted of:
) the direct thrombin inhibitor bivalirudin alone
ersus heparin plus a glycoprotein IIb/IIIa inhibitor
1:1 randomization); and 2) TAXUS EXPRESS
aclitaxel-eluting stents versus otherwise equivalent
XPRESS bare-mental stents (3:1 randomization)
Boston Scientific, Natick, Massachusetts). The
resent study cohort consists of 63 patients (99 le-
ions) with serial IVUS examinations of at least 1
ntreated nonculprit lesion in a native coronary artery
Sankyo; serves on the advisory board for Regado Biosciences; and is a cons
Merk Sharp & Dohme, and Maya Medical. Dr. Stone is a consultant f
speaker’s fees from St. Jude Medical; and grant support from Boston Scie
no relationships relevant to the contents of this paper to disclose.Manuscript received February 24, 2012; revised manuscript received Augustt baseline and at follow-up that were studied at
harite˙ University Medicine Berlin (Campus Benja-
in Franklin, Berlin, Germany) where the ethics
ommittee approved the protocol, and written in-
ormed consent was obtained from all patients.
Clinical follow-up. Clinical follow-up was performed
at 30 days, 6 months, 1 year, 2 years, and 3 years.
Routine angiographic (with or without IVUS)
follow-up was performed at 13 months or earlier if
a clinical event occurred. Pre-specified endpoints in-
cluded ischemia-driven revascularization and the
composite of major adverse cardiac events (death,
reinfarction, stroke, or stent thrombosis). An indepen-
dent clinical events committee (Cardiovas-
cular Research Foundation [CRF], New
York, New York) that was masked to
treatment assignment adjudicated all ad-
verse events from original source docu-
ments and procedural angiograms.
IVUS image acquisition. After intracoro-
ary nitroglycerin, a phased-array, 20-
Hz, 3.2-F IVUS catheter (Eagle Eye,
olcano Corporation, Rancho Cordova,
alifornia) was placed into the distal
oronary artery and pulled back to the
orto-ostial junction using an R-100
otorized catheter pullback device (Vol-
ano Corporation) at a speed of 0.5
m/s. During pull back, grayscale IVUS
as recorded, raw radiofrequency data
ere captured at the top of the R-wave,
nd reconstruction of the color-coded
ap by an IVUS data recorder was
erformed (In-Vision Gold, Volcano
orporation). The grayscale IVUS and
aptured radiofrequency data were writ-
en onto a CD-R or DVD-R and sent to
n independent IVUS core laboratory
CRF) for quantitative and qualitative
nalyses.
Grayscale and IVUS analyses. Off-line grayscale and
IVUS analyses were performed using: 1) QCU-
CMS (Medis, Leiden, the Netherlands) for con-
touring; 2) pcVH 2.1 software (Volcano Corpo-
ration) for contouring and data output; and
3) proprietary qVH software (qVH 2.5, developed and
nt for AstraZeneca, Abbott, Johnson & Johnson,
olcano Corporation. Dr. Maehara has received
c. All other authors have reported that they have
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88validated at CRF) for qualitative segmental assess-
ment and quantitative data output. Corresponding
baseline and follow-up images were identified by
the distance from 2 fiduciary landmarks such as side
branches and stent edges. Quantitative grayscale
IVUS measurements of lumen, external elastic
membrane (EEM), and plaque and media (defined
as EEM minus lumen) cross-sectional area (CSA)
and plaque burden (defined as plaque and media
divided by EEM) were performed for every re-
corded frame. IVUS analysis was also performed for
every recorded frame. Volumes were calculated
using Simpson’s rule and normalized for analysis
length. The 4 IVUS plaque components were
color-coded as white (dense calcium [DC]), red
(NC), light green (fibrofatty [FF]), and dark green
(fibrotic tissue [FT]), and reported as CSA and
percentage of total plaque CSA and volume. Vol-
umetric grayscale and IVUS analyses were per-
formed only for lesions in which motorized pull
back was consistent and reliable.
Deﬁnition of lesion types. Lesions were classified by
experienced, independent observers (Z.Z. and
.M.) on the basis of plaque composition. Interob-
erver variability was good ( 0.87), and disagree-
ents were resolved by consensus discussion. Fi-
roatheromas (TCFA and thick-cap fibroatheroma
ThCFA]) contained 10% confluent NC in at
east 3 consecutive frames. Because the window size
urrently applied for the selection of the region of
nterest and the eventual tissue map or IVUS image
econstruction using this system and catheter is
pproximately 246 m in the radial direction, it was
not possible to detect fibrous cap thickness65 m
the typical pathological definition of a thin fibrous
ap) (9). Therefore, TCFA was defined as a fibro-
theroma without virtual histology evidence of a
brous cap, with30° NC abutting the lumen in at
east 3 consecutive frames (12,14). ThCFA was
efined as a fibroatheroma with a definable fibrous
ap. Fibrotic plaque had mainly FT with 10%
onfluent NC, 15% FF tissue, and 10% conflu-
nt DC. Fibrocalcific plaque had mainly FT with
10% confluent DC, but 10% confluent NC. All
ther plaques were classified as pathological intimal
hickening (PIT), which was mainly a mixture of
T and FF (15%) with 10% confluent NC and
10% confluent DC. Fibroatheromas were consid-
red multiple and distinct if they were separated by
t least 3 consecutive image slices containing a
ifferent fibroatheroma subtype (TCFA and/or
hCFA) or a nonfibroatheroma phenotype.IVUS phenotypes and their evolution were as-
essed at 2 levels: lesion level and fibroatheroma
evel. For lesion-level IVUS classification, the entire
esion was evaluated. We identified untreated, non-
ulprit lesions as having a plaque burden 40% in
t least 3 consecutive frames (1.5 mm in length)
nd 5 mm from the stent edge. Lesions were
onsidered separate if there was a 5-mm-long
egment with 40% plaque burden between them.
lesion could contain more than 1 fibroatheroma.
ibroatheromas were considered multiple and dis-
inct if they were separated by at least 3 consecutive
rames containing a different lesion phenotype (14).
n lesions that contained more than 1 fibroathe-
oma subtype, the following hierarchy was used: a
CFA took precedence over ThCFA, and any
broatheroma took precedence over any nonfibro-
theroma. If there was no fibroatheroma in the
ntire lesion, the virtual histology classification at
he minimum lumen area (MLA) site was evaluated
nd defined as fibrotic plaque, fibrocalcific plaque,
r PIT. Because a lesion could contain more than 1
broatheroma, the evolution of each fibroatheroma
ithin a lesion was also assessed.
Table 1. Baseline Patient Clinical Characteristics (N  63)
First randomization (to bivalirudin) 33 (52.4%)
Second randomization (to paclitaxel-
eluting stent)
51 (81.0%)
Age, yrs 62.7 [52.1–69.2]
Male 53 (84.1%)
Diabetes 12 (19.0%)
Hyperlipidemia 29 (46.0%)
Hypertension 39 (61.9%)
Current smoker 37 (58.7%)
Prior myocardial infarction 2 (3.2%)
Prior percutaneous coronary intervention 4 (6.3%)
Prior coronary artery bypass grafting 3 (4.8%)
Time from symptom onset to ﬁrst balloon
inﬂation (hours)
4.1 [3.1–8.1]
Killip class 1 62 (98.4%)
Renal insufﬁciency* 1 (1.6%)
Ejection fraction, % 65.4 [54.9–68.0]
Body mass index 27.0 [24.5–29.3]
Medications at discharge
Statin 62 (98.4%)
Any thienopyridine 63 (100%)
Aspirin 63 (98.4%)
Medications at 1 year
Any thienopyridine 54 (85.7%)
Aspirin 62 (98.4%)
Values are n (%) or median [interquartile range]. *Renal insufﬁciency was
deﬁned as a creatinine clearance of 60 ml/min as calculated with the use of
the Cockcroft-Gault equation.
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89Statistical analysis. Statistical analysis was per-
ormed using SAS software, version 9.1 (SAS
nstitute, Cary, North Carolina). Categorical vari-
bles are presented as frequencies and were com-
ared with the chi-square or Fisher exact test.
ontinuous variables were presented as medians
nd interquartile ranges, and were compared using
he Wilcoxon signed rank test. For lesion- and
broatheroma-level data, a model with a general-
zed estimating equation approach was used to
ompensate for any potential cluster effect of mul-
iple fibroatheromas or lesions in the same patient
sing an exchangeable working correlation struc-
ure; data were presented as least square means with
5% confidential interval (15). A p value0.05 was
onsidered statistically significant.
R E S U L T S
Patient and lesion characteristics. Overall, 99 non-
ulprit, untreated lesions in 73 target vessels in 63
Table 2. Changes in Quantitative Grayscale and IVUS Findings B
Baseli
Lesion length, mm 9.9 [8.6–
Minimum lumen CSA, mm2 8.1 [7.4–
Mean lumen CSA, mm3/mm 9.9 [9.2–
Mean EEM CSA, mm3/mm 19.8 [18.3–
Mean plaquemedia CSA, mm3/mm 9.9 [9.0–
Plaque burden, % 49 [48–
NC at MLA site, % 14 [12–
NC at maximum NC site, % 22 [20–
NC volume, mm3 8.1 [6.3–
Mean NC CSA, mm3/mm 0.8 [0.7–
NC volume, % 14 [12–
Dense calcium volume, % 6 [5–
Fibrous tissue volume, % 59 [58–
Fibrofatty volume, % 21 [19–
Values are median [interquartile range].
CSA  cross sectional area; EEM  external elastic membrane; IVUS  intravas
Table 3. Evolution of the Lesion-Level IVUS Phenotype
Baseline TCFA Th
TCFA 41 (41%) 32
ThCFA 41 (41%) 18
PIT 16 (16%) 3
Fibrocalciﬁc 1 (1%) 0
Total 99 53 (54%) 34
Values are n or n (%).
IVUS  intravascular ultrasound-virtual histology; PIT  pathological intimalthin-cap ﬁbroatheroma.atients were identified and analyzed by grayscale
nd IVUS at baseline and follow-up. A total of 59
onculprit lesions were located in the right coronary
rtery, 19 nonculprit lesions were located in the left
nterior descending coronary artery, 9 nonculprit
esions were located in the left circumflex coronary
rtery, and 12 nonculprit lesions were located in the
eft main coronary artery. There were 3 predomi-
ant IVUS phenotypes at baseline: TCFA (n 
1), ThCFA (n  41), or PIT (n  16), whereas 1
additional lesion was classified as fibrocalcific. At
follow-up, there were 3 new lesions; 1 was a
ThCFA and 2 were PITs.
Baseline clinical characteristics are listed in Table 1.
From the baseline to follow-up imaging study, the
MLA decreased significantly (from 8.1 [7.4, 8.8]
mm2 to 7.8 [7.2, 8.4] mm2, p  0.01); this was
associated with an increase in the percent NC,
whether assessed at the MLA site (14% [12, 16] to
19% [17, 22], p 0.0001), over the entire length of
een Baseline and Follow-Up
Follow-Up p Value
] 9.8 [8.4–11.0] 0.69
7.8 [7.2–8.4] 0.01
] 9.4 [8.8–10.1] 0.0001
] 19.0 [17.6–20.4] 0.0001
] 9.6 [8.7–10.5] 0.03
50 [49–51] 0.34
19 [17–22] 0.0001
27 [25–29] 0.0001
10.3 [8.2–12.5] 0.003
1.1 [0.9–1.3] 0.0001
18 [17–20] 0.0001
10 [9–11] 0.0001
58 [56–60] 0.04
14 [12–16] 0.0001
ultrasound-virtual histology; MLA  minimum lumen area; NC  necrotic core.
Follow-Up
PIT Fibrotic Fibrocalciﬁc
0 2 0
2 1 0
6 0 0
0 0 1
) 8 (8%) 3 (3%) 1 (1%)
kening; ThCFA  thick-cap ﬁbroatheroma; TCFA  virtual histology–derivedetw
ne
11.2
8.8]
10.6
21.3
10.8
51]
16]
24]
9.9]
1.0]
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90the lesion (14% [12, 16] to 18% [17, 20], p 
0.0001), or at the maximum NC site (22% [20, 24]
to 27% [25, 29], p 0.0001) (Table 2). The change
of NC volume was negatively correlated to the
change of fibrofatty plaque volume (R  0.783,
p  0.0001) The frequency of lesions that were
classified as TCFA increased from 41% at baseline
to 54% at 13-month follow-up, whereas the pro-
portion of ThCFAs and PIT lesions decreased from
41% to 34% and from 16% to 8%, respectively
(Table 3). Among the TCFA lesions, 12.5% (5 of
40) of lesions at baseline and 7.8% (4 of 51) of
lesions at follow-up had an MLA 4 mm2; and
7.5% (3 of 40) of lesions at baseline and 13.7% of
lesions (7 of 51) at follow-up had a plaque burden
of 70% at the MLA site.
Evolution of lesion-level IVUS phenotype. The tem-
poral progression of nonculprit lesion-level IVUS
phenotype is shown in Table 3. At baseline, 41
lesions were classified as TCFA. At follow-up, 32
lesions (78%) were still classified as TCFA, whereas
9 lesions (22%) evolved into ThCFAs or fibrous
plaques. An additional 21 lesions were newly clas-
Figure 1. Evolution of 32 Lesions Classiﬁed as TCFA at Baseline
Despite no change in lesion phenotype classiﬁcation, within the les
lesions had an increase in arc of NC abutting to the lumen or an in
neous response with part of the TCFA showing a decrease in NC ab
progression. Six (19%) lesions had a partial increase of ﬁbrous cap
NC  necrotic core; ThCFA  thick-cap ﬁbroatheroma; TCFA  virtsified as TCFA at 13-month follow-up, developing dfrom either PIT (n  3, 19% of baseline PITs) or
ThCFA (n  18, 44% of baseline ThCFAs)
phenotypes. Among the 32 TCFA that did not
change their overall phenotypical classification
during follow-up, 37% had an evolution in ap-
pearance suggesting an increase in instability:
1) progression (n  12, 37%), an increase in arc
r length of NC abutting to the lumen (implying
n increase in the size of the thin cap of the
broatheroma), or an increase in the length of the
CFA; or 2) decrease and increase of fibrous cap
hickness (n  4, 13%), a heterogeneous response
uch that part of the TCFA had a decrease in NC
butting the lumen (increase of fibrous cap thick-
ess) or a reduction in TCFA length, while part of
he TCFA had a decrease in fibrous cap thickness.
onversely, there was a partial increase of the
brous cap thickness without any progression in 6
CFA (19%) and no change in 10 TCFA (31%).
his is summarized in Figure 1.
At baseline, there were 41 nonculprit lesions that
ere classified as ThCFAs. At follow-up, 18 of
hese ThCFAs evolved into TCFA (Fig. 2) with 2
at Follow-Up
, there were qualitative and quantitative changes. Twelve (37%)
se in the length of the TCFA. Four (13%) lesions had a heteroge-
ng the lumen or reduction in TCFA length and part of the TCFA
ness without any progression. Ten (31%) lesions had no changes.
histology-derived thin-cap ﬁbroatheroma.and
ions
crea
utti
thickifferent patterns: 1) new TCFA within the lesion,
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91either circumferentially (n  7, 39%) or longitudi-
nally (n  6, 33%), but at a site unrelated to the
baseline ThCFA; or 2) disappearance of fibrous cap
at the site of the baseline ThCFA, converting the
lesion into a TCFA (n  5, 28%). Conversely, 20
(49%) baseline ThCFAs were still classified as
ThCFA at follow-up, and 3 (7%) evolved into other
stable phenotypes.
At baseline there were 16 lesions that were
classified as PIT. Of these lesions, 3 (19%)
evolved into a TCFA, 76 (43%) evolved into a
ThCFA, and 6 (38%) were still classified as a PIT
at follow-up.
TCFA distribution at the ﬁbroatheroma level. As
hown in Figure 3, approximately 50% of TCFA
ere located in the proximal 20 mm of the coronary
rtery both at baseline and at follow-up. Using the
istance from the coronary ostium to the maximum
C site, TCFA that healed during follow-up
ended to be more distally located than those that
id not change (36.2 [24.2, 48.2] mm vs. 25.7
18.9, 32.6] mm, p  0.12). The distance between
newly developed TCFA at follow-up compared
with persistent TCFA from baseline was not sig-
nificantly different: 27.8 [18.9, 36.8] mm versus
Figure 2. New TCFA at Follow-Up
At follow-up, there were 18 new TCFA. Among them, 7 (39%) lesion
change. Another 5 (28%) TCFA evolved from a ThCFA with disappe
lesions, there was a new TCFA at a site that previously did not hav
PIT  pathologic intimal thickening; other abbreviations as in Figur24.7 [17.7, 31.7] mm, p  0.50.IVUS ﬁndings of patients with late clinical events.
During 3 years of follow-up, 4 unplanned revascu-
larizations were required for progressive or unstable
angina arising from these 99 nonculprit lesions. In
2 cases, the phenotypes progressed from ThCFAs
to TCFA at the time of event; in 1 case, the
phenotype progressed from PIT to ThCFA; and 1
case was a TCFA both at baseline and at the time
of the event. The grayscale and IVUS findings in
these 4 lesions are shown in Table 4.
D I S C U S S I O N
This is the first report, to our knowledge, in which
serial (baseline and follow-up) IVUS was used to
assess the dynamic nature of nonculprit coronary
artery lesion morphology in patients presenting
with STEMI. The major findings of our analysis
are: 1) more than 82% of untreated, nonculprit
lesions in patients with STEMI were fibroathero-
mas at baseline (half of which were TCFAs), with
the majority demonstrating a lack of healing and/or
an increase in unstable phenotype during 13
months of follow-up; and 2) fibroatheromas that
became more stable in appearance over time tended
ad a new TCFA in addition to the baseline ThCFA that did not
ce of the ﬁbrous cap at the site of the baseline ThCFA. In 6 (33%)
y ﬁbroatheroma (e.g., PIT that evolved into a TCFA).s h
aran
e anto be located more distally, whereas fibroatheromas
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92that did not change or that became more unstable
tended to be located more proximally.
Characterization of the nonculprit lesion phenotype. In
he current prospective study in patients with
TEMI, 82% of secondary, nonculprit lesions were
broatheromas, with half of these (41%) having a
CFA phenotype at baseline. The high rate of
broatheromas are consistent with an earlier study
y Asakura et al. (16), who reported that in 20
oninfarcted vessels, yellow, nondisrupted plaques
s seen by angioscopy were present in most patients
month after a myocardial infarction (MI). By
ontrast, in the IVUS study by Kubo et al. (13) in
atients mainly with stable ischemic heart disease,
nly 43% and 9% of secondary lesions had a
hCFA and TCFA phenotype at baseline, respec-
ively. Thus, these data suggest that patients with
TEMI compared with those without acute coro-
ary syndromes are significantly more likely to have
broatheromas and TCFAs at untreated, noncul-
rit lesion sites. These studies are also consistent
ith reports of simultaneous plaque ruptures in
ome patients with STEMI (8,17).
Other intravascular imaging studies have com-
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tally than TCFA that did not change. Abbreviations as in Figure 1.ared secondary lesions in stable versus unstable satients. Nakamura et al. (18) showed that TCFA
ere more common in ACS patients compared
ith stable patients (64.6% vs 35.7%, p  0.006).
ong et al. (8) performed a 3-vessel grayscale IVUS
tudy of 235 patients (122 acute MI, 113 stable
ngina); secondary plaque ruptures were present in
1 MI patients (17%) versus 6 stable patients (5%,
 0.008). In a 3-vessel IVUS study, Hong et al.
19) reported a higher frequency of TCFA and
laque ruptures in secondary lesions in patients with
CS compared with stable angina (69% vs. 45%,
nd 8% vs. 4%, respectively, both p 0.001). Using
ntegrated backscatter IVUS (another radiofre-
uency IVUS technique), Ando et al. (20) showed a
arger percent lipid area (p  0.03) and a smaller
ercent fibrotic plaque area (p 0.04) in nonculprit
esions in ACS patients compared with stable an-
ina patients. Finally, Kubo et al. (21), using optical
oherence tomography (OCT), reported that fi-
rous cap thickness (111  65 vs. 181  70 m,
p  0.002) was significantly thinner and the fre-
uency of OCT-derived TCFA (38% vs. 6%, p 
.030) was significantly greater in acute MI than in
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93Serial intravascular imaging assessment of nonculprit
lesion phenotype. There have been few serial intra-
ascular imaging studies assessing changes in lesion
henotype of unruptured, secondary plaques in
table or unstable patients (13,22–25). Using serial
baseline and follow-up) IVUS in patients with
ostly stable ischemic heart disease, Kubo et al. (13)
eported that most nonculprit TCFA stabilized or
ealed during 13 months of follow-up. By contrast, in
he current study in patients with STEMI, nonculprit
CFA remained unchanged or became more unstable
Table 4. Baseline and Follow-Up Findings of Patients With Late
Vessel
Time from baseline, days
IVUS phenotype
Minimum lumen area site Lumen CSA, mm2
Plaque burden, %
% NC
Maximum NC site Lumen CSA, mm2
Plaque burden, %
%NC
LAD  left anterior descending; LM  left main coronary artery; RCA  right c
19%
Baseline
19%
29% 22%
43%
50%
9% 7%
Follow-up
Stable Angina
Fibrous
Fibrocalcific
PIT
ThCFA
TCFA
Figure 4. Comparison of 2 Serial IVUS Studies Reported From t
Patients with stable angina are shown on the left. At baseline, only
TCFA “healed,” and 5 (25%) TCFA remained unchanged (13). Patien
from 41% at baseline to 54% at 13-month follow-up, with 32 (78%)
and 21 new TCFA developing from either PITs or ThCFAs. Abbreviationver time, while more stable lesions evolved into more
nstable phenotypes. Of note, both of these studies
ere analyzed at the same core laboratory (CRF)
sing the same analytic techniques and definitions. A
omparison of these 2 studies showing the difference
etween stable and unstable patients is shown in
igure 4.
The current study is also consistent with 2 small
erial angioscopy studies. In 1 study in 48 patients
ith ACS and previous MI, the 12-month healing
ate of nonculprit, ruptured plaques was only 30%
ascularization Events in Nonculprit Lesions
Case #
1 2 3
RCA LAD RCA
404 786 936
Baseline ThCFA ThCFA PIT
Follow-up TCFA TCFA ThCF
Baseline 6.9 3.4 7
Follow-up 5.6 3.3 5
Baseline 68.2 58.1 59
Follow-up 68.0 53.9 62
Baseline 6.0 20.0 3
Follow-up 11.0 26.0 23
Baseline 9.0 3.4 9
Follow-up 8.2 3.7 6
Baseline 60.7 58.1 44
Follow-up 59.5 52.1 58
Baseline 12.0 20.0 10
Follow-up 33.0 36.0 24
ary artery; other abbreviations as in Tables 2 and 3.
41%
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om the current analysis are shown on the right. TCFA increased
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94(22). In the second study in 13 consecutive acute
MI patients, the number of nonculprit yellow
plaques did not change from post-reperfusion to
6-month follow-up (24).
TCFA location and “increase of ﬁbrous cap.” In the
current study of patients with STEMI, approximately
50% of TCFA were in the proximal 20 mm of a
coronary artery at baseline. Numerous pathological,
angiographic, and imaging studies have shown a
similar, proximal predisposition of TCFAs, acute
occlusions, or plaque ruptures. In a human autopsy
study, Cheruvu et al. (5) reported that 50% of TCFAs
were present within the first 22 mm of the left anterior
descending and left circumflex arteries and the first 31
mm of the right coronary artery. In another ex vivo
study using histology, IVUS, and OCT, Kume et al.
(26) reported that 70% of TCFAs clustered in the first
30 mm of a coronary artery. Wang et al. (27) analyzed
208 consecutive STEMI patients and found that
angiographic occlusions tended to cluster within the
proximal third of each coronary artery. In a 3-vessel
grayscale IVUS study, Hong et al. (28) evaluated the
axial location of plaque rupture in 392 patients; plaque
ruptures occurred mainly in proximal segments of the
left anterior descending coronary artery, the proximal
half of the left circumflex, and the proximal and distal
segments of right coronary artery. In a subsequent
IVUS analysis, Hong et al. (20) also reported that 83%
of TCFA were located mainly within 40 mm of the
coronary ostium. The current study extends these
findings by showing that proximal TCFA tended to
progress to more unstable phenotypes, whereas distal
TCFA did not.
Technical considerations. In the current study, IVUS
henotype evolution was assessed at 2 levels: lesion
evel and fibroatheroma level because a single lesion
ay contain more than 1 discrete fibroatheroma. If
here was more than 1 fibroatheroma subtype
ithin a given lesion, a TCFA took precedence over
hCFA; thus, for example, even if a lesion con-
ained multiple ThCFAs at baseline, the evolution
f only 1 ThCFA into a TCFA changed the overall
esion phenotype classification into a TCFA. SuchCardiol 2003;41:15S–22S. Farb A, Schwartzncreased the frequency of TCFA classification
ignificantly, from 41% at baseline to 54% at 13-
onth follow-up at the lesion level.
Study limitations. Several limitations of the present
tudy should be noted. Despite the fact that the
ORIZONS-AMI is one of the largest IVUS
ulticenter trials, this substudy is of modest size
nd from a single center. Potential selection bias
annot be excluded. Most of the patients had IVUS
n only 1 vessel, and none had 3-vessel imaging.
he present results should therefore be considered
xploratory and hypothesis generating. Details on
ipid levels and corresponding pharmacotherapy are
ot available. IVUS generates only 1 image per
very heart beat, thereby severely limiting coregis-
ration and potentially causing misalignment be-
ween baseline and follow-up images. There were
oo few clinical events to permit a well-powered
xploration of the relationship between recurrent
vents and plaque morphology as disclosed by
VUS. The anatomic locations and distributions of
he lesions in this study vary from the typical
istribution of culprit lesions as well as from the
istribution of culprit lesions in the HORIZONS
rial. As a result, lesions in this substudy may be
ubjected to different shear stress and other athero-
enic factors that may influence progression com-
ared with culprits There was no control group, and
he number of new TCFA was too small to identify
redictors of the transition from stable to vulnerable
henotype.
C O N C L U S I O N S
Untreated, nonculprit lesions in patients with STEMI
are frequently fibroatheromas and typically become
increasingly unstable during 13-month follow-up, with
a decrease in MLA, increase in NC, and overall devolu-
tion to a TCFA morphology.
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